Comparison Between Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients With Acute Coronary Syndrome

Phase 4

Completed

• Conditions: Mi Q Wave
• Interventions: Device: Turbox CRP kit; Drug: atorvastatin 40 mg; Drug: rosuvastatin 20 mg,

• Registration Number: NCT06053983
• Lead Sponsor: Rawalpindi Medical College

Brief Summary

This study will help us to compare atorvastatin and rosuvastatin in terms of their ability to reduce biomarkers of inflammation in patients of acute coronary syndrome

Detailed Description

Not available

Study Timeline

• Study Start: 2023-01-01
• Primary Completion: 2023-08-01
• Study Completion: 2023-08-01
• Study First Submitted: 2023-09-19
• Study First Submitted QC: 2023-09-19
• Study First Posted: 2023-09-26
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-15
• Last Update Posted: 2023-10-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 126

Inclusion Criteria

1. Patients with age 18 years and above, of both genders, diagnosed with acute coronary syndrome (as per operational definition) who were not taking statins previously.
2. Patients who sign written informed consent to participate in the study.

Exclusion Criteria

• 1.Patients who are taking either statins and/or any other drug which lower serum lipid levels, patients with a history of statin hypersensitivity, patients in whom statins are contraindicated.

  2.Patients who will be surgically managed will be also excluded. 3.if coronary revascularization will be planned or anticipated at the time of screening.

  4.Pregnant or lactating women. 5.Patients having concomitant infections which cause the rise of inflammatory markers.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
atorvastatin 40 mg	atorvastatin 40 mg	-
rosuvastatin 20 mg	Turbox CRP kit	-
atorvastatin 40 mg	Turbox CRP kit	-
rosuvastatin 20 mg	rosuvastatin 20 mg,	-

Primary Outcome Measures

Name	Time	Method
Mean Change C-reactive protein	AFTER 4 WEEKS	hs -CRP (mg/l)

Trial Locations

Locations (1)

Rawalpindi Medical University; 🇵🇰 Rawalpindi, Pakistan